Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials

S.-D. Hong, Y.-S. Wang, H.-Y. Zhao, Y.-Y. Zhao, Q.-M. Wang, Y.-X. Ma, Y.-S. Li, Y. Huang, Y.-P. Yang, Z.-M. Fu, L.-K. Chen, F. Zhou, J. Yang, X.-Y. Li, X. Hou, N.-N. Zhou, L.-H. Sun, G.-F. Zhang, J.-W. Cui, L. Wu, G. Chen, Y.-X. Zhang, H.-Y. Wang, D.-Q. Lv, J.-H. Shi, B. Jiang, C. Li, X.-L. Li, K.-J. Tang, Y. Yu, Y.-H. Ji, Z.-Y. He, Y. Zhu, H. Zhu, S. Xiao, C.-C. Zhou, L. Zhang, W.-F. Fang

Open source

DOI: 10.1016/j.annonc.2026.01.009
Published: 2026-06
Container: Annals of Oncology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.annonc.2026.01.009,
  title = {Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials},
  author = {S.-D. Hong and Y.-S. Wang and H.-Y. Zhao and Y.-Y. Zhao and Q.-M. Wang and Y.-X. Ma and Y.-S. Li and Y. Huang and Y.-P. Yang and Z.-M. Fu and L.-K. Chen and F. Zhou and J. Yang and X.-Y. Li and X. Hou and N.-N. Zhou and L.-H. Sun and G.-F. Zhang and J.-W. Cui and L. Wu and G. Chen and Y.-X. Zhang and H.-Y. Wang and D.-Q. Lv and J.-H. Shi and B. Jiang and C. Li and X.-L. Li and K.-J. Tang and Y. Yu and Y.-H. Ji and Z.-Y. He and Y. Zhu and H. Zhu and S. Xiao and C.-C. Zhou and L. Zhang and W.-F. Fang},
  year = {2026},
  journal = {Annals of Oncology},
  doi = {10.1016/j.annonc.2026.01.009},
  url = {https://doi.org/10.1016/j.annonc.2026.01.009}
}

RIS

TY  - JOUR
TI  - Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
AU  - S.-D. Hong
AU  - Y.-S. Wang
AU  - H.-Y. Zhao
AU  - Y.-Y. Zhao
AU  - Q.-M. Wang
AU  - Y.-X. Ma
AU  - Y.-S. Li
AU  - Y. Huang
AU  - Y.-P. Yang
AU  - Z.-M. Fu
AU  - L.-K. Chen
AU  - F. Zhou
AU  - J. Yang
AU  - X.-Y. Li
AU  - X. Hou
AU  - N.-N. Zhou
AU  - L.-H. Sun
AU  - G.-F. Zhang
AU  - J.-W. Cui
AU  - L. Wu
AU  - G. Chen
AU  - Y.-X. Zhang
AU  - H.-Y. Wang
AU  - D.-Q. Lv
AU  - J.-H. Shi
AU  - B. Jiang
AU  - C. Li
AU  - X.-L. Li
AU  - K.-J. Tang
AU  - Y. Yu
AU  - Y.-H. Ji
AU  - Z.-Y. He
AU  - Y. Zhu
AU  - H. Zhu
AU  - S. Xiao
AU  - C.-C. Zhou
AU  - L. Zhang
AU  - W.-F. Fang
PY  - 2026
JO  - Annals of Oncology
DO  - 10.1016/j.annonc.2026.01.009
UR  - https://doi.org/10.1016/j.annonc.2026.01.009
ER  -

APA

Hong, S., Wang, Y., Zhao, H., Zhao, Y., Wang, Q., Ma, Y., Li, Y., Huang, Y., Yang, Y., Fu, Z., Chen, L., Zhou, F., Yang, J., Li, X., Hou, X., Zhou, N., Sun, L., Zhang, G., Cui, J., Wu, L., Chen, G., Zhang, Y., Wang, H., Lv, D., Shi, J., Jiang, B., Li, C., Li, X., Tang, K., Yu, Y., Ji, Y., He, Z., Zhu, Y., Zhu, H., Xiao, S., Zhou, C., Zhang, L., & Fang, W. (2026). Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials. Annals of Oncology. https://doi.org/10.1016/j.annonc.2026.01.009

Source records

crossref · retrieved 2026-09-27T13:39:59.569Z